Development and validation of a prognostic nomogram for progression-free survival in patients with advanced renal cell carcinoma treated with pazopanib Journal Article


Authors: Kattan, M. W.; Sternberg, C. N.; Mehmud, F.; Bhatt, K.; McCann, L.; Motzer, R. J.
Article Title: Development and validation of a prognostic nomogram for progression-free survival in patients with advanced renal cell carcinoma treated with pazopanib
Abstract: Objective: To develop and validate a prognostic nomogram for predicting the probability of 12-month progression-free survival (PFS) for patients receiving first-line pazopanib for advanced renal cell carcinoma (RCC). Methods: Statistical modeling was performed with data from 557 pazopanib-treated patients in the phase 3 COMPARZ trial. A multivariable Cox model was fit using known prognostic indicators. Variables included neutrophil count, serum levels of albumin and alkaline phosphatase, time from diagnosis to treatment, and bone metastases. Data from the pazopanib arm of a placebo-controlled phase 3 trial were used for validation. Results: The model included ten prognostic variables and was plotted as a nomogram for predicting the probability of 12-month PFS. Calibration plots suggested reasonable correspondence between predicted probabilities and actual proportions of PFS. The concordance index for 12-month PFS was 0.625. Significant associations (p < 0.05) were observed between PFS and bone metastases, time from diagnosis to treatment, albumin, and alkaline phosphatase. Albumin and alkaline phosphatase appeared to be influential predictors. Conclusion: The nomogram predicts, with reasonable accuracy, PFS in patients with advanced RCC receiving pazopanib, based on their baseline clinical characteristics. © 2015 S. Karger AG, Basel.
Keywords: adult; cancer chemotherapy; cancer survival; controlled study; major clinical study; placebo; sunitinib; advanced cancer; bone metastasis; progression free survival; multiple cycle treatment; neutrophil count; randomized controlled trial; continuous infusion; renal cell carcinoma; kidney carcinoma; alkaline phosphatase; albumin; pazopanib; alkaline phosphatase blood level; phase 3 clinical trial; double blind procedure; angiogenesis inhibitors; nomogram; albumin blood level; cancer prognosis; prognosis; human; priority journal; article; comparz
Journal Title: Oncology
Volume: 89
Issue: 4
ISSN: 0030-2414
Publisher: S. Karger AG  
Date Published: 2015-09-01
Start Page: 235
End Page: 241
Language: English
DOI: 10.1159/000430989
PROVIDER: scopus
PUBMED: 26088013
DOI/URL:
Notes: Export Date: 2 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1248 Motzer